• Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Attralus Inc. logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 14, 2022 Press Releases

PDF Version AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis AT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected patients with diverse types of systemic amyloidosis, by...

Recent Posts

  • Final Results Of The First-In-Human Study Of The Amyloid-Reactive Peptide 124I-p5+14, (Iodine[124I] Evuzamitide; AT-01) For The Detection Of Systemic Amyloidosis
  • Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
  • Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis Using iodine (124I) evuzamitide (124I-p5+14) Identifies Organ-Specific Amyloid Regression
  • Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
  • Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors
SCIENCE

Approach
Pan-Amyloid Removal (PAR)
Pan-Amyloid Diagnostic

PIPELINE

 

NEWS

Press Releases
Posters & Publications
In the News

HOME
AMYLOIDOSIS
CAREERS
CONTACT
  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow

Attralus, Inc.
‍
50 Francisco Street
Suite 450
San Francisco, CA 94133

©2022 Attralus, Inc.  All Rights Reserved.